314 related articles for article (PubMed ID: 9288760)
1. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.
Liu H; Moy P; Kim S; Xia Y; Rajasekaran A; Navarro V; Knudsen B; Bander NH
Cancer Res; 1997 Sep; 57(17):3629-34. PubMed ID: 9288760
[TBL] [Abstract][Full Text] [Related]
2. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
[TBL] [Abstract][Full Text] [Related]
3. Measurement of prostate-specific membrane antigen in the serum with a new antibody.
Murphy GP; Tino WT; Holmes EH; Boynton AL; Erickson SJ; Bowes VA; Barren RJ; Tjoa BA; Misrock SL; Ragde H; Kenny GM
Prostate; 1996 Apr; 28(4):266-71. PubMed ID: 8602402
[TBL] [Abstract][Full Text] [Related]
4. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
[TBL] [Abstract][Full Text] [Related]
5. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.
Chang SS; Reuter VE; Heston WD; Bander NH; Grauer LS; Gaudin PB
Cancer Res; 1999 Jul; 59(13):3192-8. PubMed ID: 10397265
[TBL] [Abstract][Full Text] [Related]
6. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA).
Tino WT; Huber MJ; Lake TP; Greene TG; Murphy GP; Holmes EH
Hybridoma; 2000 Jun; 19(3):249-57. PubMed ID: 10952413
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas.
Beckett ML; Lipford GB; Haley CL; Schellhammer PF; Wright GL
Cancer Res; 1991 Feb; 51(4):1326-33. PubMed ID: 1705172
[TBL] [Abstract][Full Text] [Related]
8. Constitutive and antibody-induced internalization of prostate-specific membrane antigen.
Liu H; Rajasekaran AK; Moy P; Xia Y; Kim S; Navarro V; Rahmati R; Bander NH
Cancer Res; 1998 Sep; 58(18):4055-60. PubMed ID: 9751609
[TBL] [Abstract][Full Text] [Related]
9. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.
Muraro R; Kuroki M; Wunderlich D; Poole DJ; Colcher D; Thor A; Greiner JW; Simpson JF; Molinolo A; Noguchi P
Cancer Res; 1988 Aug; 48(16):4588-96. PubMed ID: 3396010
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5.
Lopes AD; Davis WL; Rosenstraus MJ; Uveges AJ; Gilman SC
Cancer Res; 1990 Oct; 50(19):6423-9. PubMed ID: 1698122
[TBL] [Abstract][Full Text] [Related]
11. Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.
Kinoshita Y; Kuratsukuri K; Newman N; Rovito PM; Kaumaya PT; Wang CY; Haas GP
Prostate Cancer Prostatic Dis; 2005; 8(4):359-63. PubMed ID: 16172607
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody CC188 binds a carbohydrate epitope expressed on the surface of both colorectal cancer stem cells and their differentiated progeny.
Xu M; Yuan Y; Xia Y; Achilefu S
Clin Cancer Res; 2008 Nov; 14(22):7461-9. PubMed ID: 19010863
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors.
Modak S; Kramer K; Gultekin SH; Guo HF; Cheung NK
Cancer Res; 2001 May; 61(10):4048-54. PubMed ID: 11358824
[TBL] [Abstract][Full Text] [Related]
14. Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens.
Zhang S; Zhang HS; Cordon-Cardo C; Ragupathi G; Livingston PO
Clin Cancer Res; 1998 Nov; 4(11):2669-76. PubMed ID: 9829729
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies to human prostate and bladder tumor-associated antigens.
Starling JJ; Sieg SM; Beckett ML; Schellhammer PF; Ladaga LE; Wright GL
Cancer Res; 1982 Aug; 42(8):3084-9. PubMed ID: 7046915
[TBL] [Abstract][Full Text] [Related]
16. A monoclonal antibody directed against a human cell membrane antigen prevents cell substrate adhesion and tumor invasion.
De Potter CR; Schelfhout AM; De Smet FH; Van Damme S; de Ridder L; Dhont E; van Emmelo J
Am J Pathol; 1994 Jan; 144(1):95-103. PubMed ID: 8291615
[TBL] [Abstract][Full Text] [Related]
17. Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules.
Burke PA; Gregg JP; Bakhtiar B; Beckett LA; Denardo GL; Albrecht H; De Vere White RW; De Nardo SJ
Int J Oncol; 2006 Jul; 29(1):49-55. PubMed ID: 16773184
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical characterization of two monoclonal antibodies, P25.48 and P25.91, which define a new prostate-specific antigen.
Bazinet M; Cote RJ; Cordon-Cardo C; Myc A; Fair WR; Old LJ
Cancer Res; 1988 Dec; 48(23):6938-42. PubMed ID: 2460231
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin G3 monoclonal antibody directed to Tn antigen (tumor-associated alpha-N-acetylgalactosaminyl epitope) that does not cross-react with blood group A antigen.
Takahashi HK; Metoki R; Hakomori S
Cancer Res; 1988 Aug; 48(15):4361-7. PubMed ID: 3390832
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
Huang X; Bennett M; Thorpe PE
Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
